Aldeyra Therapeutics’ Stock Surges Over 50 % as Exclusive Option Agreement with AbbVie Unveiled
In a significant development, Aldeyra Therapeutics, a leading biotechnology company specializing in the discovery and development of innovative therapies for immune-mediated diseases, announced today that
